ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1345

Upadacitinib as Monotherapy and in Combination with Non-biologic DMARDs for the Treatment of Psoriatic Arthritis: Subgroup Analysis from Two Phase 3 Trials
Abstract Number: 0209

Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate: Results at 84 Weeks
Abstract Number: 0207

Upadacitinib Monotherapy in Methotrexate-naïve Patients with Rheumatoid Arthritis: Results at 72 Weeks
Abstract Number: 0784

Upregulation of Tyro3TK on CD14+CD16- Monocytes Promotes Osteoclast Formation in Rheumatoid Arthritis
Abstract Number: 0817

Uptake of Janus Kinase Inhibitors for Management of Rheumatoid Arthritis in Australia
Abstract Number: 0664

Uric Acid Level Is Associated with Severity of Heart Failure with Preserved Ejection Fraction
Abstract Number: 1816

Urine Biomarkers of Tubulointersitital Damage in Lupus Nephritis
Abstract Number: 0029

Urine Proteomic Classifiers Predict Renal Histological Activity and Chronicity Indices and May Predict Treatment Response in Lupus Nephritis
Abstract Number: 0936

Urine Proteomics and Single Cell Transcriptomics Identify IL-16 as a Biomarker for Lupus Nephritis
Abstract Number: 0872

Usage of Corticosteroids and Hospitalisation Duration in Adult Patients with Systemic Lupus Erythematosus (SLE) in Latvia
Abstract Number: 1384

Usage, Needs and Preferences Regarding Physical Therapy in Patients with Systemic Sclerosis
Abstract Number: 1614

Use of a Best Practice Alert to Encourage Transition Planning and Readiness
Abstract Number: 1597

Use of a Clinical Dashboard Improves the Documentation of Disease Severity Scores and May Facilitate the Implementation of Treat to Target Therapy
Abstract Number: 1782

Use of a Patient-reported Survey to Document Contraceptive Use and Interest in Pregnancy to Identify Patients with Unmet Pregnancy Prevention and Planning Needs
Abstract Number: 0441

Use of an Integrated Care Management Program to Uncover and Address Social Determinants of Health for Individuals with Lupus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].